Literature DB >> 2809684

Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma.

L J Helman1, P S Cohen, S D Averbuch, M J Cooper, H R Keiser, M A Israel.   

Abstract

No reliable gross or microscopic features distinguish benign from malignant pheochromocytomas. The diagnosis of malignant pheochromocytoma is based solely on the presence of regional or distant metastases. This study evaluated the expression of neuropeptide Y messenger RNA (mRNA) in nine benign and 11 malignant pheochromocytomas and has found that neuropeptide Y mRNA was expressed in all nine benign tumors but in only four of 11 malignant tumors (P = .0084). These data suggest that the determination of neuropeptide Y expression in the evaluation of patients with pheochromocytoma may have prognostic significance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2809684     DOI: 10.1200/JCO.1989.7.11.1720

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  10 in total

1.  Neuropeptide Y as a Biomarker and Therapeutic Target for Neuroblastoma.

Authors:  Susana Galli; Arlene Naranjo; Collin Van Ryn; Jason U Tilan; Emily Trinh; Chao Yang; Jessica Tsuei; Sung-Hyeok Hong; Hongkun Wang; Ewa Izycka-Swieszewska; Yi-Chien Lee; Olga C Rodriguez; Chris Albanese; Joanna Kitlinska
Journal:  Am J Pathol       Date:  2016-10-12       Impact factor: 4.307

Review 2.  Differential diagnosis of pheochromocytomas and paragangliomas.

Authors:  A M McNichol
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

3.  Production, characterization, and expression of neuropeptide Y by human pheochromocytoma.

Authors:  P deS Senanayake; J Denker; E L Bravo; R M Graham
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

4.  Assessment of adrenal surgery on creatinine clearance in patients with phaeochromocytoma.

Authors:  T Nakada; H Kaneko; Y Kubota; M Watanabe; I Sasagawa; T Yagisawa; H Yamanaka; K Imai
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

Review 5.  Biology of tumors of the peripheral nervous system.

Authors:  G M Brodeur; J F Moley
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

6.  [Malignant adrenal pheochromocytoma--problems in evaluating clinical diagnosis and morphologic extent].

Authors:  M Brückner; B C Padberg; M Dürig; S Schröder
Journal:  Langenbecks Arch Chir       Date:  1993

7.  Proliferation Markers and Their Uses in the Study of Endocrine Tumors.

Authors:  Giuseppe Pelosi; Giuseppe Zamboni
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

Review 8.  Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.

Authors:  Aoife J Lowery; Siun Walsh; Enda W McDermott; Ruth S Prichard
Journal:  Oncologist       Date:  2013-04-10

Review 9.  Intricacies of the Molecular Machinery of Catecholamine Biosynthesis and Secretion by Chromaffin Cells of the Normal Adrenal Medulla and in Pheochromocytoma and Paraganglioma.

Authors:  Annika M A Berends; Graeme Eisenhofer; Lauren Fishbein; Anouk N A V D Horst-Schrivers; Ido P Kema; Thera P Links; Jacques W M Lenders; Michiel N Kerstens
Journal:  Cancers (Basel)       Date:  2019-08-06       Impact factor: 6.639

10.  Serum Exosomal lncRNA AC007099.1 Regulates the Expression of Neuropeptide-Related FAP, as a Potential Biomarker for Hepatocarcinogenesis.

Authors:  Luqian Li; Fei Xiao; Guolian Liu; Yufeng Chen
Journal:  Dis Markers       Date:  2022-02-10       Impact factor: 3.434

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.